查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1867590

肝細胞生長因子：全球市佔率及排名、總收入及需求預測（2025-2031年）

Hepatocyte Growth Factor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 105 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球肝細胞生長因子 (HGF) 市場規模估計為 7,580 萬美元，預計到 2031 年將達到 4.26 億美元，在 2025 年至 2031 年的預測期內，複合年成長率將達到 28.0%。

本報告對近期關稅調整和國際戰略反制措施對肝細胞生長因子 (HGF) 的跨境產業佈局、資本配置模式、區域經濟相互依存關係和供應鏈重組進行了全面評估。

肝細胞生長因子（HGF）（或稱散播因子（SF））是一種旁分泌細胞生長、運動和形態發生因子。它由間質細胞分泌，主要針對上皮細胞和內皮細胞，但也作用於造血前驅細胞和T細胞。研究表明，它在胚胎器官發育（尤其是肌肉生成）、成體器官再生和創傷治療中發揮重要作用。

目前，針對HGF通路藥物的研發主要分為神經再生和腫瘤兩大領域。臨床研發管線主要集中在糖尿病神經病變病變、肌萎縮側索硬化症（ALS）、脊髓損傷、中風以及包括非小細胞肺癌（NSCLC）和胃癌在內的多種固體癌等適應症。在全球範圍內，Helixmith、Anges MG和Kringle Pharma等公司正在開發用於治療神經系統疾病的基因療法和重組蛋白。 Atira Pharma和AVEO正在開發針對HGF/c-Met軸的小分子和抗體藥物，而Exelixis和Molecular Partners則採用多標靶策略，致力於廣泛的腫瘤治療。北京北地製藥代表了中國在該領域的早期開拓者。在多種治療模式和平行研發路徑並存的背景下，多個在研化合物已進入後期臨床試驗或獲得有條件核可階段，這表明其在再生醫學和罕見疾病領域具有巨大的商業潛力。

本報告旨在按地區/國家、類型和應用對全球肝細胞生長因子 (HGF) 市場進行全面分析，重點關注總銷售量、收入、價格、市場佔有率和主要企業的排名。

肝細胞生長因子市場規模、估算和預測以銷售（千）和收入（百萬美元）為單位呈現，基準年為2024年，並包含2020年至2031年的歷史數據和預測數據。報告採用定量和定性分析相結合的方法，幫助讀者制定業務/成長策略，評估競爭激烈的市場格局，分析自身在當前市場中的地位，並就肝細胞生長因子做出明智的商業決策。

市場區隔

公司

  • Helixsmith
  • Exelixis
  • AnGes MG
  • Athira Pharma
  • AVEO Pharmaceuticals
  • Molecular Partners
  • Kringle Pharma
  • Beijing Northland

按類型分類的細分市場

  • 第三階段（進行中）
  • 第二階段（已通過核准）
  • 第二階段（進行中）
  • 第一階段
  • 臨床前
  • 已通過核准/已上市

應用領域

  • 腫瘤學
  • 循環系統
  • 中樞神經系統
  • 血液疾病
  • 其他

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Hepatocyte Growth Factor was estimated to be worth US$ 75.8 million in 2024 and is forecast to a readjusted size of US$ 426 million by 2031 with a CAGR of 28.0% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Hepatocyte Growth Factor cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Hepatocyte growth factor (HGF) (or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells and T cells. It has been shown to have a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration, and in wound healing.

Current drug development targeting the HGF pathway is bifurcated into neuroregeneration and oncology tracks, with clinical pipelines focused on indications such as diabetic neuropathy, ALS, spinal cord injury, stroke, and various solid tumors including NSCLC and gastric cancer. Globally, companies like Helixmith, AnGes MG, and Kringle Pharma are advancing gene therapies and recombinant proteins for neurological indications. Athira Pharma and AVEO are developing small molecules and antibodies targeting the HGF/c-Met axis, while Exelixis and Molecular Partners pursue broader oncology strategies via multi-target approaches. Beijing Northland represents China's early-stage involvement in this area. The landscape is marked by diversified modalities and parallel development paths, with several assets reaching late-stage trials or conditional approvals, indicating strong commercialization potential in regenerative medicine and rare diseases.

This report aims to provide a comprehensive presentation of the global market for Hepatocyte Growth Factor, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Hepatocyte Growth Factor by region & country, by Type, and by Application.

The Hepatocyte Growth Factor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatocyte Growth Factor.

Market Segmentation

By Company

  • Helixsmith
  • Exelixis
  • AnGes MG
  • Athira Pharma
  • AVEO Pharmaceuticals
  • Molecular Partners
  • Kringle Pharma
  • Beijing Northland

Segment by Type

  • Phase III (Ongoing)
  • Phase II (Approved)
  • Phase II (Ongoing)
  • Phase 1
  • Preclinical
  • Approved / Marketed

Segment by Application

  • Oncology
  • Cardiovascular
  • Central Nervous System
  • Hematological Disorders
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Hepatocyte Growth Factor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Hepatocyte Growth Factor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Hepatocyte Growth Factor in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Hepatocyte Growth Factor Product Introduction
  • 1.2 Global Hepatocyte Growth Factor Market Size Forecast
    • 1.2.1 Global Hepatocyte Growth Factor Sales Value (2020-2031)
    • 1.2.2 Global Hepatocyte Growth Factor Sales Volume (2020-2031)
    • 1.2.3 Global Hepatocyte Growth Factor Sales Price (2020-2031)
  • 1.3 Hepatocyte Growth Factor Market Trends & Drivers
    • 1.3.1 Hepatocyte Growth Factor Industry Trends
    • 1.3.2 Hepatocyte Growth Factor Market Drivers & Opportunity
    • 1.3.3 Hepatocyte Growth Factor Market Challenges
    • 1.3.4 Hepatocyte Growth Factor Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Hepatocyte Growth Factor Players Revenue Ranking (2024)
  • 2.2 Global Hepatocyte Growth Factor Revenue by Company (2020-2025)
  • 2.3 Global Hepatocyte Growth Factor Players Sales Volume Ranking (2024)
  • 2.4 Global Hepatocyte Growth Factor Sales Volume by Company Players (2020-2025)
  • 2.5 Global Hepatocyte Growth Factor Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Hepatocyte Growth Factor Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Hepatocyte Growth Factor Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Hepatocyte Growth Factor
  • 2.9 Hepatocyte Growth Factor Market Competitive Analysis
    • 2.9.1 Hepatocyte Growth Factor Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Hepatocyte Growth Factor Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatocyte Growth Factor as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Phase III (Ongoing)
    • 3.1.2 Phase II (Approved)
    • 3.1.3 Phase II (Ongoing)
    • 3.1.4 Phase 1
    • 3.1.5 Preclinical
    • 3.1.6 Approved / Marketed
  • 3.2 Global Hepatocyte Growth Factor Sales Value by Type
    • 3.2.1 Global Hepatocyte Growth Factor Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Hepatocyte Growth Factor Sales Value, by Type (2020-2031)
    • 3.2.3 Global Hepatocyte Growth Factor Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Hepatocyte Growth Factor Sales Volume by Type
    • 3.3.1 Global Hepatocyte Growth Factor Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Hepatocyte Growth Factor Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Hepatocyte Growth Factor Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Hepatocyte Growth Factor Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Oncology
    • 4.1.2 Cardiovascular
    • 4.1.3 Central Nervous System
    • 4.1.4 Hematological Disorders
    • 4.1.5 Others
  • 4.2 Global Hepatocyte Growth Factor Sales Value by Application
    • 4.2.1 Global Hepatocyte Growth Factor Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Hepatocyte Growth Factor Sales Value, by Application (2020-2031)
    • 4.2.3 Global Hepatocyte Growth Factor Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Hepatocyte Growth Factor Sales Volume by Application
    • 4.3.1 Global Hepatocyte Growth Factor Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Hepatocyte Growth Factor Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Hepatocyte Growth Factor Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Hepatocyte Growth Factor Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Hepatocyte Growth Factor Sales Value by Region
    • 5.1.1 Global Hepatocyte Growth Factor Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Hepatocyte Growth Factor Sales Value by Region (2020-2025)
    • 5.1.3 Global Hepatocyte Growth Factor Sales Value by Region (2026-2031)
    • 5.1.4 Global Hepatocyte Growth Factor Sales Value by Region (%), (2020-2031)
  • 5.2 Global Hepatocyte Growth Factor Sales Volume by Region
    • 5.2.1 Global Hepatocyte Growth Factor Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Hepatocyte Growth Factor Sales Volume by Region (2020-2025)
    • 5.2.3 Global Hepatocyte Growth Factor Sales Volume by Region (2026-2031)
    • 5.2.4 Global Hepatocyte Growth Factor Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Hepatocyte Growth Factor Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Hepatocyte Growth Factor Sales Value, 2020-2031
    • 5.4.2 North America Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Hepatocyte Growth Factor Sales Value, 2020-2031
    • 5.5.2 Europe Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Hepatocyte Growth Factor Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Hepatocyte Growth Factor Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Hepatocyte Growth Factor Sales Value, 2020-2031
    • 5.7.2 South America Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Hepatocyte Growth Factor Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Hepatocyte Growth Factor Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Hepatocyte Growth Factor Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Hepatocyte Growth Factor Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Hepatocyte Growth Factor Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Hepatocyte Growth Factor Sales Value, 2020-2031
    • 6.3.2 United States Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Hepatocyte Growth Factor Sales Value, 2020-2031
    • 6.4.2 Europe Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Hepatocyte Growth Factor Sales Value, 2020-2031
    • 6.5.2 China Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Hepatocyte Growth Factor Sales Value, 2020-2031
    • 6.6.2 Japan Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Hepatocyte Growth Factor Sales Value, 2020-2031
    • 6.7.2 South Korea Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Hepatocyte Growth Factor Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Hepatocyte Growth Factor Sales Value, 2020-2031
    • 6.9.2 India Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Hepatocyte Growth Factor Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Helixsmith
    • 7.1.1 Helixsmith Company Information
    • 7.1.2 Helixsmith Introduction and Business Overview
    • 7.1.3 Helixsmith Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Helixsmith Hepatocyte Growth Factor Product Offerings
    • 7.1.5 Helixsmith Recent Development
  • 7.2 Exelixis
    • 7.2.1 Exelixis Company Information
    • 7.2.2 Exelixis Introduction and Business Overview
    • 7.2.3 Exelixis Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Exelixis Hepatocyte Growth Factor Product Offerings
    • 7.2.5 Exelixis Recent Development
  • 7.3 AnGes MG
    • 7.3.1 AnGes MG Company Information
    • 7.3.2 AnGes MG Introduction and Business Overview
    • 7.3.3 AnGes MG Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 AnGes MG Hepatocyte Growth Factor Product Offerings
    • 7.3.5 AnGes MG Recent Development
  • 7.4 Athira Pharma
    • 7.4.1 Athira Pharma Company Information
    • 7.4.2 Athira Pharma Introduction and Business Overview
    • 7.4.3 Athira Pharma Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Athira Pharma Hepatocyte Growth Factor Product Offerings
    • 7.4.5 Athira Pharma Recent Development
  • 7.5 AVEO Pharmaceuticals
    • 7.5.1 AVEO Pharmaceuticals Company Information
    • 7.5.2 AVEO Pharmaceuticals Introduction and Business Overview
    • 7.5.3 AVEO Pharmaceuticals Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 AVEO Pharmaceuticals Hepatocyte Growth Factor Product Offerings
    • 7.5.5 AVEO Pharmaceuticals Recent Development
  • 7.6 Molecular Partners
    • 7.6.1 Molecular Partners Company Information
    • 7.6.2 Molecular Partners Introduction and Business Overview
    • 7.6.3 Molecular Partners Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Molecular Partners Hepatocyte Growth Factor Product Offerings
    • 7.6.5 Molecular Partners Recent Development
  • 7.7 Kringle Pharma
    • 7.7.1 Kringle Pharma Company Information
    • 7.7.2 Kringle Pharma Introduction and Business Overview
    • 7.7.3 Kringle Pharma Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Kringle Pharma Hepatocyte Growth Factor Product Offerings
    • 7.7.5 Kringle Pharma Recent Development
  • 7.8 Beijing Northland
    • 7.8.1 Beijing Northland Company Information
    • 7.8.2 Beijing Northland Introduction and Business Overview
    • 7.8.3 Beijing Northland Hepatocyte Growth Factor Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Beijing Northland Hepatocyte Growth Factor Product Offerings
    • 7.8.5 Beijing Northland Recent Development

8 Industry Chain Analysis

  • 8.1 Hepatocyte Growth Factor Industrial Chain
  • 8.2 Hepatocyte Growth Factor Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Hepatocyte Growth Factor Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Hepatocyte Growth Factor Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Hepatocyte Growth Factor Market Trends
  • Table 2. Hepatocyte Growth Factor Market Drivers & Opportunity
  • Table 3. Hepatocyte Growth Factor Market Challenges
  • Table 4. Hepatocyte Growth Factor Market Restraints
  • Table 5. Global Hepatocyte Growth Factor Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Hepatocyte Growth Factor Revenue Market Share by Company (2020-2025)
  • Table 7. Global Hepatocyte Growth Factor Sales Volume by Company (2020-2025) & (K Units)
  • Table 8. Global Hepatocyte Growth Factor Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Hepatocyte Growth Factor Price by Company (2020-2025) & (USD/Unit)
  • Table 10. Key Manufacturers Hepatocyte Growth Factor Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Hepatocyte Growth Factor Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Hepatocyte Growth Factor
  • Table 13. Global Hepatocyte Growth Factor Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatocyte Growth Factor as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Hepatocyte Growth Factor Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Hepatocyte Growth Factor Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Hepatocyte Growth Factor Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Hepatocyte Growth Factor Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Hepatocyte Growth Factor Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Hepatocyte Growth Factor Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
  • Table 22. Global Hepatocyte Growth Factor Sales Volume by Type (2020-2025) & (K Units)
  • Table 23. Global Hepatocyte Growth Factor Sales Volume by Type (2026-2031) & (K Units)
  • Table 24. Global Hepatocyte Growth Factor Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Hepatocyte Growth Factor Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Hepatocyte Growth Factor Price by Type (2020-2025) & (USD/Unit)
  • Table 27. Global Hepatocyte Growth Factor Price by Type (2026-2031) & (USD/Unit)
  • Table 28. Global Hepatocyte Growth Factor Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Hepatocyte Growth Factor Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Hepatocyte Growth Factor Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Hepatocyte Growth Factor Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Hepatocyte Growth Factor Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Hepatocyte Growth Factor Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
  • Table 34. Global Hepatocyte Growth Factor Sales Volume by Application (2020-2025) & (K Units)
  • Table 35. Global Hepatocyte Growth Factor Sales Volume by Application (2026-2031) & (K Units)
  • Table 36. Global Hepatocyte Growth Factor Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Hepatocyte Growth Factor Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Hepatocyte Growth Factor Price by Application (2020-2025) & (USD/Unit)
  • Table 39. Global Hepatocyte Growth Factor Price by Application (2026-2031) & (USD/Unit)
  • Table 40. Global Hepatocyte Growth Factor Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Hepatocyte Growth Factor Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Hepatocyte Growth Factor Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Hepatocyte Growth Factor Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Hepatocyte Growth Factor Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Hepatocyte Growth Factor Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
  • Table 46. Global Hepatocyte Growth Factor Sales Volume by Region (2020-2025) & (K Units)
  • Table 47. Global Hepatocyte Growth Factor Sales Volume by Region (2026-2031) & (K Units)
  • Table 48. Global Hepatocyte Growth Factor Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Hepatocyte Growth Factor Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Hepatocyte Growth Factor Average Price by Region (2020-2025) & (USD/Unit)
  • Table 51. Global Hepatocyte Growth Factor Average Price by Region (2026-2031) & (USD/Unit)
  • Table 52. Key Countries/Regions Hepatocyte Growth Factor Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Hepatocyte Growth Factor Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Hepatocyte Growth Factor Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Hepatocyte Growth Factor Sales Volume, (2020-2025) & (K Units)
  • Table 56. Key Countries/Regions Hepatocyte Growth Factor Sales Volume, (2026-2031) & (K Units)
  • Table 57. Helixsmith Company Information
  • Table 58. Helixsmith Introduction and Business Overview
  • Table 59. Helixsmith Hepatocyte Growth Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 60. Helixsmith Hepatocyte Growth Factor Product Offerings
  • Table 61. Helixsmith Recent Development
  • Table 62. Exelixis Company Information
  • Table 63. Exelixis Introduction and Business Overview
  • Table 64. Exelixis Hepatocyte Growth Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 65. Exelixis Hepatocyte Growth Factor Product Offerings
  • Table 66. Exelixis Recent Development
  • Table 67. AnGes MG Company Information
  • Table 68. AnGes MG Introduction and Business Overview
  • Table 69. AnGes MG Hepatocyte Growth Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 70. AnGes MG Hepatocyte Growth Factor Product Offerings
  • Table 71. AnGes MG Recent Development
  • Table 72. Athira Pharma Company Information
  • Table 73. Athira Pharma Introduction and Business Overview
  • Table 74. Athira Pharma Hepatocyte Growth Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 75. Athira Pharma Hepatocyte Growth Factor Product Offerings
  • Table 76. Athira Pharma Recent Development
  • Table 77. AVEO Pharmaceuticals Company Information
  • Table 78. AVEO Pharmaceuticals Introduction and Business Overview
  • Table 79. AVEO Pharmaceuticals Hepatocyte Growth Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 80. AVEO Pharmaceuticals Hepatocyte Growth Factor Product Offerings
  • Table 81. AVEO Pharmaceuticals Recent Development
  • Table 82. Molecular Partners Company Information
  • Table 83. Molecular Partners Introduction and Business Overview
  • Table 84. Molecular Partners Hepatocyte Growth Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 85. Molecular Partners Hepatocyte Growth Factor Product Offerings
  • Table 86. Molecular Partners Recent Development
  • Table 87. Kringle Pharma Company Information
  • Table 88. Kringle Pharma Introduction and Business Overview
  • Table 89. Kringle Pharma Hepatocyte Growth Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 90. Kringle Pharma Hepatocyte Growth Factor Product Offerings
  • Table 91. Kringle Pharma Recent Development
  • Table 92. Beijing Northland Company Information
  • Table 93. Beijing Northland Introduction and Business Overview
  • Table 94. Beijing Northland Hepatocyte Growth Factor Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 95. Beijing Northland Hepatocyte Growth Factor Product Offerings
  • Table 96. Beijing Northland Recent Development
  • Table 97. Key Raw Materials Lists
  • Table 98. Raw Materials Key Suppliers Lists
  • Table 99. Hepatocyte Growth Factor Downstream Customers
  • Table 100. Hepatocyte Growth Factor Distributors List
  • Table 101. Research Programs/Design for This Report
  • Table 102. Key Data Information from Secondary Sources
  • Table 103. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Hepatocyte Growth Factor Product Picture
  • Figure 2. Global Hepatocyte Growth Factor Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Hepatocyte Growth Factor Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Hepatocyte Growth Factor Sales Volume (2020-2031) & (K Units)
  • Figure 5. Global Hepatocyte Growth Factor Sales Price (2020-2031) & (USD/Unit)
  • Figure 6. Hepatocyte Growth Factor Report Years Considered
  • Figure 7. Global Hepatocyte Growth Factor Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Hepatocyte Growth Factor Players Sales Volume Ranking (2024) & (K Units)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Hepatocyte Growth Factor Revenue in 2024
  • Figure 10. Hepatocyte Growth Factor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Phase III (Ongoing) Picture
  • Figure 12. Phase II (Approved) Picture
  • Figure 13. Phase II (Ongoing) Picture
  • Figure 14. Phase 1 Picture
  • Figure 15. Preclinical Picture
  • Figure 16. Approved / Marketed Picture
  • Figure 17. Global Hepatocyte Growth Factor Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 18. Global Hepatocyte Growth Factor Sales Value Market Share by Type, 2024 & 2031
  • Figure 19. Global Hepatocyte Growth Factor Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
  • Figure 20. Global Hepatocyte Growth Factor Sales Volume Market Share by Type, 2024 & 2031
  • Figure 21. Global Hepatocyte Growth Factor Price by Type (2020-2031) & (USD/Unit)
  • Figure 22. Product Picture of Oncology
  • Figure 23. Product Picture of Cardiovascular
  • Figure 24. Product Picture of Central Nervous System
  • Figure 25. Product Picture of Hematological Disorders
  • Figure 26. Product Picture of Others
  • Figure 27. Global Hepatocyte Growth Factor Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 28. Global Hepatocyte Growth Factor Sales Value Market Share by Application, 2024 & 2031
  • Figure 29. Global Hepatocyte Growth Factor Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
  • Figure 30. Global Hepatocyte Growth Factor Sales Volume Market Share by Application, 2024 & 2031
  • Figure 31. Global Hepatocyte Growth Factor Price by Application (2020-2031) & (USD/Unit)
  • Figure 32. North America Hepatocyte Growth Factor Sales Value (2020-2031) & (US$ Million)
  • Figure 33. North America Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031
  • Figure 34. Europe Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Europe Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031
  • Figure 36. Asia Pacific Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. Asia Pacific Hepatocyte Growth Factor Sales Value by Region (%), 2024 VS 2031
  • Figure 38. South America Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. South America Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031
  • Figure 40. Middle East & Africa Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. Middle East & Africa Hepatocyte Growth Factor Sales Value by Country (%), 2024 VS 2031
  • Figure 42. Key Countries/Regions Hepatocyte Growth Factor Sales Value (%), (2020-2031)
  • Figure 43. Key Countries/Regions Hepatocyte Growth Factor Sales Volume (%), (2020-2031)
  • Figure 44. United States Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. United States Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • Figure 46. United States Hepatocyte Growth Factor Sales Value by Application (%), 2024 VS 2031
  • Figure 47. Europe Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. Europe Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • Figure 49. Europe Hepatocyte Growth Factor Sales Value by Application (%), 2024 VS 2031
  • Figure 50. China Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 51. China Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • Figure 52. China Hepatocyte Growth Factor Sales Value by Application (%), 2024 VS 2031
  • Figure 53. Japan Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 54. Japan Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • Figure 55. Japan Hepatocyte Growth Factor Sales Value by Application (%), 2024 VS 2031
  • Figure 56. South Korea Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 57. South Korea Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • Figure 58. South Korea Hepatocyte Growth Factor Sales Value by Application (%), 2024 VS 2031
  • Figure 59. Southeast Asia Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 60. Southeast Asia Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • Figure 61. Southeast Asia Hepatocyte Growth Factor Sales Value by Application (%), 2024 VS 2031
  • Figure 62. India Hepatocyte Growth Factor Sales Value, (2020-2031) & (US$ Million)
  • Figure 63. India Hepatocyte Growth Factor Sales Value by Type (%), 2024 VS 2031
  • Figure 64. India Hepatocyte Growth Factor Sales Value by Application (%), 2024 VS 2031
  • Figure 65. Hepatocyte Growth Factor Industrial Chain
  • Figure 66. Hepatocyte Growth Factor Manufacturing Cost Structure
  • Figure 67. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 68. Bottom-up and Top-down Approaches for This Report
  • Figure 69. Data Triangulation
  • Figure 70. Key Executives Interviewed